Prazolok ER is indicated in the treatment of all grades of essential (primary) hypertension and of all grades of secondary hypertension of variec etiology.
Indications
Hypertension: Prazolok ER is indicated in the treatment of all grades of essential (primary) hypertension and of all grades of secondary hypertension of variec etiology. It can be used as the initial and sole agent or it may be employed in a treatment program in combination with a diuretic and/or other antihypertensive drugs as needed for proper patient response. Renal blood flow and glomerular filtration rate are not impaired by long-term oral administration and thus Prazolok ER can be used with safety in hypertensive patients with impaired renal function.
Prazosin causes a decrease in total peripheral vascular resistance through selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle. In hypertensive patients, blood pressure is lowered in both the supine and standing positions; this effect is more pronounced on the diastolic blood pressure. Rebound elevation of blood pressure does not occur following abrupt cessation of Prazosin therapy.
Interaction
Prazolok ER XR has been administered without any adverse drug interaction in clinical experience to date with the following:
Prazosin is contraindicated in patients with a known sensitivity to quinazolines.
The most common reactions associated with Prazolok ER therapy are dizziness, headache, drowsiness, lack of energy, weakness, palpitations and nausea. In most instances, side effects have disappeared with continued therapy or have been tolerated with no decrease in the dosage of the drug.
Although no teratogenic effects were seen in animal testing; the safety of Prazosin use during. pregnancy has not yet been established. The use of prazosin and a beta-blocker for the control of sever hypertension of 44 pregnant women revealed no drug-related fetal adnormalities or adverse effects.
Children: Prazolok ER is not recommended for the treatment of children under the age of 12 years since safe conditions for its use have not been established.
Left Ventricular Failure: Prazolok ER is not recommended in the treatment of left ventricular failure due to mechanical obstrcution such as aortic valve stenosis, mitral valve stenosis, pulmonary embolism and restrictive pericardial disease. Adequate data are not yet available to establish efficacy in patients with left ventricular failure due to a recent myocardial infarction.
Accidental ingestion of at least 50 mg of Prazolok ER in a two-year child resulted in profound drowsiness and depressed reflexes, No decrease in blood pressure was noted. Recovery was uneventful. Should overdosage lead to hypotension, support of the cardiovascular system is of first importance.
Alpha adrenoceptor blocking drugs
Keep away from light and moisture, store below 30°C. Keep away from reach out of the children.
